Beijing Hotgen Biotech Co., Ltd. (688068.SS)
CNY 123.5
(-1.2%)
CNY 123.5
(-1.2%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 202.56 Million CNY | -62.87% |
| 2022 | 545.58 Million CNY | -29.24% |
| 2021 | 771.01 Million CNY | 395.12% |
| 2020 | 155.72 Million CNY | 103.89% |
| 2019 | 76.37 Million CNY | 34.75% |
| 2018 | 56.68 Million CNY | 102.42% |
| 2017 | 28 Million CNY | -3.91% |
| 2016 | 29.14 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 166.66 Million CNY | -18.84% |
| 2024 Q1 | 205.34 Million CNY | 1.37% |
| 2024 Q3 | 150.83 Million CNY | -9.5% |
| 2023 Q1 | 300.5 Million CNY | -44.92% |
| 2023 Q2 | 270.61 Million CNY | -9.95% |
| 2023 Q4 | 202.56 Million CNY | 0.96% |
| 2023 Q3 | 200.63 Million CNY | -25.86% |
| 2023 FY | 202.56 Million CNY | -62.87% |
| 2022 Q4 | 545.58 Million CNY | 56.72% |
| 2022 Q3 | 348.12 Million CNY | -24.04% |
| 2022 Q1 | 431.68 Million CNY | -44.01% |
| 2022 Q2 | 458.29 Million CNY | 6.16% |
| 2022 FY | 545.58 Million CNY | -29.24% |
| 2021 Q2 | 451.37 Million CNY | -54.59% |
| 2021 Q1 | 994 Million CNY | 538.31% |
| 2021 FY | 771.01 Million CNY | 395.12% |
| 2021 Q3 | 247.58 Million CNY | -45.15% |
| 2021 Q4 | 771.01 Million CNY | 211.41% |
| 2020 FY | 155.72 Million CNY | 103.89% |
| 2020 Q2 | 73.86 Million CNY | -29.98% |
| 2020 Q3 | 51.43 Million CNY | -30.36% |
| 2020 Q4 | 155.72 Million CNY | 202.73% |
| 2020 Q1 | 105.48 Million CNY | 38.12% |
| 2019 Q1 | 52.85 Million CNY | -6.76% |
| 2019 FY | 76.37 Million CNY | 34.75% |
| 2019 Q4 | 76.37 Million CNY | 5.41% |
| 2019 Q3 | 72.45 Million CNY | 13.91% |
| 2019 Q2 | 63.6 Million CNY | 20.35% |
| 2018 Q4 | 56.68 Million CNY | 0.0% |
| 2018 FY | 56.68 Million CNY | 102.42% |
| 2017 FY | 28 Million CNY | -3.91% |
| 2016 FY | 29.14 Million CNY | 0.0% |